{
    "hands_on_practices": [
        {
            "introduction": "A primary challenge in managing the non-allergic rhinitis spectrum is accurately differentiating its various subtypes, such as vasomotor rhinitis from Nonallergic Rhinitis with Eosinophilia Syndrome (NARES). This exercise demonstrates how to rigorously evaluate a diagnostic tool, in this case nasal cytology, using fundamental principles of biostatistics. By calculating sensitivity, specificity, and predictive value from a hypothetical cohort, you will gain hands-on experience in assessing a test's intrinsic accuracy and understanding how its clinical usefulness changes with disease prevalence .",
            "id": "5053105",
            "problem": "A clinician is evaluating nasal cytology as a diagnostic test for Nonallergic Rhinitis with Eosinophilia Syndrome (NARES) within the non-allergic rhinitis spectrum, which also includes vasomotor rhinitis and rhinitis medicamentosa. The test considers a nasal smear positive if it shows more than $10$ eosinophils per high-power field. In a prospective cohort of $400$ adults with chronic rhinitis referred to an Ear, Nose, and Throat (ENT) clinic, all decongestants were withheld for $48$ hours to minimize acute pharmacologic effects of rhinitis medicamentosa on mucosal cells, and a reference standard based on clinical criteria plus blinded histopathology classified patients as follows:\n- True NARES: $160$ patients, of whom $136$ had positive nasal cytology and $24$ had negative nasal cytology.\n- Non-NARES: $240$ patients, of whom $48$ had positive nasal cytology and $192$ had negative nasal cytology.\n\nStarting from the formal definitions of sensitivity and specificity, compute the sensitivity and specificity of nasal cytology for diagnosing NARES from these data. Then, using Bayesâ€™ theorem as the fundamental base, derive the positive predictive value as a function of disease prevalence $p$ and evaluate it for a primary care setting where the prevalence of NARES among patients presenting with chronic rhinitis is $p=0.30$. Round your final numeric result to four significant figures and express it as a decimal fraction (no percentage sign).",
            "solution": "The problem provides data from a diagnostic accuracy study and asks for the calculation of sensitivity, specificity, and positive predictive value (PPV).\n\nFirst, we define the events and population counts based on the provided data.\nLet $D^+$ represent the event that a patient has True NARES (Disease Positive).\nLet $D^-$ represent the event that a patient does not have NARES (Disease Negative).\nLet $T^+$ represent a positive nasal cytology test result.\nLet $T^-$ represent a negative nasal cytology test result.\n\nFrom the problem statement, we are given the following counts:\nThe total number of patients with NARES is $160$.\nThe number of patients with NARES and a positive test (True Positives, $TP$) is $136$.\nThe number of patients with NARES and a negative test (False Negatives, $FN$) is $24$.\nThe total number of patients without NARES is $240$.\nThe number of patients without NARES and a positive test (False Positives, $FP$) is $48$.\nThe number of patients without NARES and a negative test (True Negatives, $TN$) is $192$.\nThe total cohort size is $160 + 240 = 400$.\n\nFirst, we compute the sensitivity and specificity of the nasal cytology test.\n\nSensitivity (Sens) is the probability of a positive test result given that the patient has the disease. It is the proportion of true positives among all diseased individuals.\n$$ \\text{Sensitivity} = P(T^+ | D^+) = \\frac{TP}{TP + FN} $$\nSubstituting the given values:\n$$ \\text{Sensitivity} = \\frac{136}{136 + 24} = \\frac{136}{160} = 0.85 $$\n\nSpecificity (Spec) is the probability of a negative test result given that the patient does not have the disease. It is the proportion of true negatives among all non-diseased individuals.\n$$ \\text{Specificity} = P(T^- | D^-) = \\frac{TN}{TN + FP} $$\nSubstituting the given values:\n$$ \\text{Specificity} = \\frac{192}{192 + 48} = \\frac{192}{240} = 0.80 $$\n\nNext, we derive the Positive Predictive Value (PPV) as a function of disease prevalence, $p$, using Bayes' theorem, and evaluate it for $p=0.30$.\nThe PPV is the probability that a patient has the disease given that they have a positive test result, $P(D^+ | T^+)$.\n\nAccording to Bayes' theorem:\n$$ P(D^+ | T^+) = \\frac{P(T^+ | D^+) P(D^+)}{P(T^+)} $$\nThe denominator, $P(T^+)$, is the overall probability of a positive test, which we expand using the law of total probability:\n$$ P(T^+) = P(T^+ | D^+) P(D^+) + P(T^+ | D^-) P(D^-) $$\nUsing the definitions of sensitivity, specificity, and prevalence ($p = P(D^+)$):\n- $P(D^-) = 1 - p$\n- $P(T^+ | D^+) = \\text{Sensitivity}$\n- $P(T^+ | D^-) = 1 - P(T^- | D^-) = 1 - \\text{Specificity}$\n\nSubstituting these into the formula for PPV:\n$$ \\text{PPV}(p) = P(D^+ | T^+) = \\frac{(\\text{Sensitivity}) \\cdot p}{(\\text{Sensitivity}) \\cdot p + (1 - \\text{Specificity}) \\cdot (1 - p)} $$\nThis is the derived expression for PPV as a function of prevalence $p$.\n\nFinally, we evaluate this expression for a prevalence of $p = 0.30$, using our calculated sensitivity ($0.85$) and specificity ($0.80$).\n$$ \\text{PPV}(0.30) = \\frac{(0.85) \\cdot (0.30)}{(0.85) \\cdot (0.30) + (1 - 0.80) \\cdot (1 - 0.30)} $$\n$$ \\text{PPV}(0.30) = \\frac{0.255}{0.255 + (0.20) \\cdot (0.70)} $$\n$$ \\text{PPV}(0.30) = \\frac{0.255}{0.255 + 0.140} $$\n$$ \\text{PPV}(0.30) = \\frac{0.255}{0.395} $$\n$$ \\text{PPV}(0.30) \\approx 0.64556962... $$\nRounding to four significant figures gives $0.6456$.\nThis result signifies that for a patient in a primary care setting (where prevalence is $30\\%$) who tests positive with nasal cytology, there is approximately a $64.56\\%$ probability that they truly have NARES.",
            "answer": "$$\n\\boxed{0.6456}\n$$"
        },
        {
            "introduction": "Advising patients on the risks of topical decongestants requires a quantitative understanding of how the probability of developing rhinitis medicamentosa (RM) increases with use. This problem introduces the logistic model, a powerful tool in epidemiology, to formalize this relationship between exposure duration and disease risk. Using clinically-informed constraints, you will derive an explicit formula for the probability of developing RM, learning to interpret the model's parameters as they relate to baseline risk and the daily increase in odds .",
            "id": "5053092",
            "problem": "A clinician is modelling the risk of Rhinitis Medicamentosa (RM) within the spectrum of non-allergic rhinitis as a function of duration of topical nasal decongestant exposure. Assume the following well-tested statistical modelling framework grounded in epidemiologic risk modelling: let the probability of RM at $d$ days of continuous use be $p(d)$, with the odds defined by $o(d) = \\frac{p(d)}{1 - p(d)}$, and the log-odds (logit) specified to change linearly with exposure duration, that is, $\\ln\\!\\left(\\frac{p(d)}{1-p(d)}\\right) = \\alpha + \\beta d$, where $\\alpha$ and $\\beta$ are parameters to be determined from clinically observed constraints. For clinically realistic calibration, take $p(2) = 0.02$ (rare early occurrence) and $p(14) = 0.5$ (half of prolonged users manifest RM).\n\nStarting only from the definitions of odds and log-odds above and the two calibration constraints, derive a closed-form analytic expression for $p(d)$ as a function of $d$ and constants, expressed in terms of elementary functions. Then, in words, interpret the meanings of $\\alpha$ and $\\beta$ within the clinical context of RM and non-allergic rhinitis. Provide your final expression for $p(d)$ as a single closed-form analytic expression. No rounding is required. The variable $d$ represents time in days of decongestant use; the probability $p(d)$ is unitless.",
            "solution": "The core of the model is the linear relationship for the log-odds (logit) of developing Rhinitis Medicamentosa (RM):\n$$\n\\ln\\left(\\frac{p(d)}{1-p(d)}\\right) = \\alpha + \\beta d\n$$\nwhere $p(d)$ is the probability of RM after $d$ days of continuous use. We are given two data points to determine the parameters $\\alpha$ and $\\beta$:\n1. At $d = 2$ days, the probability is $p(2) = 0.02$.\n2. At $d = 14$ days, the probability is $p(14) = 0.5$.\n\nWe use these points to create a system of two linear equations in $\\alpha$ and $\\beta$.\n\nFor the first data point ($d=2$):\nThe odds are $o(2) = \\frac{p(2)}{1-p(2)} = \\frac{0.02}{1 - 0.02} = \\frac{1}{49}$.\nThe log-odds are $\\ln(o(2)) = \\ln\\left(\\frac{1}{49}\\right) = -\\ln(49)$.\nThis gives our first equation:\n$$\n\\alpha + 2\\beta = -\\ln(49) \\quad (1)\n$$\nFor the second data point ($d=14$):\nThe odds are $o(14) = \\frac{p(14)}{1-p(14)} = \\frac{0.5}{1 - 0.5} = 1$.\nThe log-odds are $\\ln(o(14)) = \\ln(1) = 0$.\nThis gives our second equation:\n$$\n\\alpha + 14\\beta = 0 \\quad (2)\n$$\nNow we solve the system of equations. From equation (2), we express $\\alpha$ in terms of $\\beta$: $\\alpha = -14\\beta$.\nSubstitute this into equation (1):\n$$\n(-14\\beta) + 2\\beta = -\\ln(49) \\implies -12\\beta = -\\ln(49) \\implies \\beta = \\frac{\\ln(49)}{12}\n$$\nNow, we find $\\alpha$:\n$$\n\\alpha = -14\\beta = -14 \\left(\\frac{\\ln(49)}{12}\\right) = -\\frac{7}{6}\\ln(49)\n$$\nWith the parameters determined, the log-odds model is:\n$$\n\\ln\\left(\\frac{p(d)}{1-p(d)}\\right) = -\\frac{7}{6}\\ln(49) + \\frac{d}{12}\\ln(49) = \\ln(49) \\left(\\frac{d - 14}{12}\\right)\n$$\nTo find $p(d)$, we exponentiate to solve for the odds, $o(d)$:\n$$\no(d) = \\frac{p(d)}{1-p(d)} = \\exp\\left(\\ln(49) \\left(\\frac{d - 14}{12}\\right)\\right) = 49^{\\frac{d-14}{12}}\n$$\nUsing the relationship $p(d) = o(d)/(1+o(d))$, we substitute our expression for $o(d)$. An equivalent and more compact form is obtained by expressing this as $p(d) = 1/(1 + 1/o(d))$:\n$$\np(d) = \\frac{1}{1 + 49^{-\\frac{d-14}{12}}} = \\frac{1}{1 + 49^{\\frac{14-d}{12}}}\n$$\nThis is the closed-form analytic expression for $p(d)$.\n\nThe parameters $\\alpha$ and $\\beta$ have clear clinical interpretations. The parameter $\\alpha$ represents the log-odds of having RM at day 0. It sets the baseline risk before prolonged exposure begins. The parameter $\\beta$ is the slope of the logit function; it quantifies the daily increase in the log-odds of developing RM. Specifically, for each additional day of use, the odds of having RM are multiplied by a factor of $\\exp(\\beta) = 49^{1/12} \\approx 1.38$, which means the odds increase by about 38% per day.",
            "answer": "$$\n\\boxed{p(d) = \\frac{1}{1 + 49^{\\frac{14-d}{12}}}}\n$$"
        },
        {
            "introduction": "The management of rhinitis medicamentosa is dominated by the challenge of weaning patients from topical decongestants without causing intolerable rebound congestion. This practice employs pharmacokinetic/pharmacodynamic (PK/PD) modeling to provide a quantitative framework for comparing weaning strategies. By solving a system of differential equations that represent drug effect and receptor desensitization, you will calculate the total congestion burden for both abrupt cessation and a gradual taper, revealing the biophysical principles that should guide this common clinical decision .",
            "id": "5053084",
            "problem": "A patient with rhinitis medicamentosa secondary to prolonged overuse of a topical nasal alpha-adrenergic agonist is transitioned off therapy. Model the pharmacokinetic/pharmacodynamic (PK/PD, Pharmacokinetic/Pharmacodynamic) consequences on nasal congestion using a linear, one-compartment effect model for drug effect and a first-order receptor desensitization model. Let the instantaneous drug effect be $D(t)$ and the receptor-driven desensitization (which increases congestion) be $R(t)$. Assume the following foundational, well-tested dynamics:\n\n- The drug effect compartment follows $ \\frac{dD}{dt} = -k_{d} D + u(t) $, where $k_{d} = \\ln(2)/t_{1/2,d}$ and $t_{1/2,d}$ is the effect-compartment half-life.\n- The receptor desensitization follows $ \\frac{dR}{dt} = -k_{r} R + g D $, where $k_{r} = \\ln(2)/t_{1/2,r}$ and $t_{1/2,r}$ is the desensitization recovery half-life. Choose $g$ so that in steady state with constant input the system satisfies $R_{\\mathrm{ss}} = D_{\\mathrm{ss}}$.\n\nThe patient has been on chronic overuse before $t=0$ at a constant average input $u_{\\mathrm{ss}}$ that maintained a steady state $D_{\\mathrm{ss}} = 1$ and $R_{\\mathrm{ss}} = 1$. At $t=0$, two weaning strategies are compared over the horizon $t \\in [0, T]$ with $T = 72$:\n\n1. Abrupt cessation: $u(t) = 0$ for $t \\in [0, T]$.\n2. Gradual dose spacing: approximate the reduction in dosing frequency (from every $8$ hours to every $24$ hours) by a reduction in average input to $u(t) = u_{\\mathrm{ss}}/3$ for $t \\in [0, T]$.\n\nAssume $t_{1/2,d} = 6$ hours and $t_{1/2,r} = 24$ hours. Define the congestion severity relative to baseline as $C(t) = a R(t) - b D(t)$ with $a = 1$ and $b = 1$. Let the area under the effect curve (AUEC) for congestion be $Q = \\int_{0}^{T} C(t)\\, dt$. Using the stated dynamics and initial conditions $D(0^{-}) = 1$, $R(0^{-}) = 1$, compute the ratio $Q_{\\mathrm{abrupt}}/Q_{\\mathrm{gradual}}$. Express the final ratio as a pure number with no units. No rounding is required.",
            "solution": "We start from the stated linear differential equations. The drug effect compartment follows $ \\frac{dD}{dt} = -k_{d} D + u(t) $ and the receptor desensitization follows $ \\frac{dR}{dt} = -k_{r} R + g D $. To enforce $R_{\\mathrm{ss}} = D_{\\mathrm{ss}}$ under a constant input $u_{\\mathrm{ss}}$, note that steady state satisfies $0 = -k_{d} D_{\\mathrm{ss}} + u_{\\mathrm{ss}}$ and $0 = -k_{r} R_{\\mathrm{ss}} + g D_{\\mathrm{ss}}$. Thus $D_{\\mathrm{ss}} = u_{\\mathrm{ss}}/k_{d}$ and $R_{\\mathrm{ss}} = (g/k_{r}) D_{\\mathrm{ss}}$. For $R_{\\mathrm{ss}} = D_{\\mathrm{ss}}$, we require $g = k_{r}$.\n\nGiven chronic overuse prior to $t=0$, we have $D(0^{-}) = 1$, $R(0^{-}) = 1$, and $u_{\\mathrm{ss}} = k_{d}$ from $D_{\\mathrm{ss}} = 1$.\n\nDefine $T = 72$. The congestion relative to baseline is $C(t) = R(t) - D(t)$ with $a = b = 1$. The AUEC is $Q = \\int_{0}^{T} C(t)\\, dt$.\n\nAbrupt cessation case:\n\n- Input: $u(t) = 0$ for $t \\in [0, T]$.\n- Drug effect: $ \\frac{dD}{dt} = -k_{d} D $ with $D(0) = 1$, hence $D_{\\mathrm{abrupt}}(t) = \\exp(-k_{d} t)$.\n- Receptor desensitization: $ \\frac{dR}{dt} = -k_{r} R + k_{r} D_{\\mathrm{abrupt}}(t)$ with $R(0) = 1$.\n\nSolving this system, the congestion $C_{\\mathrm{abrupt}}(t) = R_{\\mathrm{abrupt}}(t) - D_{\\mathrm{abrupt}}(t)$ is found to be:\n$$\nC_{\\mathrm{abrupt}}(t) = \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\exp(-k_{d} t) - \\exp(-k_{r} t) \\right].\n$$\nThe AUEC for abrupt cessation over $[0, T]$ is the integral of $C_{\\mathrm{abrupt}}(t)$:\n$$\nQ_{\\mathrm{abrupt}} = \\int_{0}^{T} C_{\\mathrm{abrupt}}(t)\\, dt\n= \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\int_{0}^{T} \\exp(-k_{d} t)\\, dt - \\int_{0}^{T} \\exp(-k_{r} t)\\, dt \\right].\n$$\nUsing $ \\int_{0}^{T} \\exp(-\\alpha t)\\, dt = \\frac{1 - \\exp(-\\alpha T)}{\\alpha} $, we obtain\n$$\nQ_{\\mathrm{abrupt}} = \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\frac{1 - \\exp(-k_{d} T)}{k_{d}} - \\frac{1 - \\exp(-k_{r} T)}{k_{r}} \\right].\n$$\n\nGradual dose spacing case:\n\n- Input is approximated as $u(t) = u_{\\mathrm{ss}}/3 = k_{d}/3$ for $t \\in [0, T]$.\n- Drug effect satisfies $ \\frac{dD}{dt} = -k_{d} D + k_{d}/3 $ with $D(0) = 1$. The steady-state level for this input is $D_{\\infty} = (k_{d}/3)/k_{d} = 1/3$. The solution is:\n$$\nD_{\\mathrm{grad}}(t) = D_{\\infty} + \\left( D(0) - D_{\\infty} \\right) \\exp(-k_{d} t) = \\frac{1}{3} + \\frac{2}{3} \\exp(-k_{d} t).\n$$\n- Receptor desensitization satisfies $ \\frac{dR}{dt} = -k_{r} R + k_{r} D_{\\mathrm{grad}}(t) $ with $R(0) = 1$.\n\nSolving for the congestion $C_{\\mathrm{grad}}(t) = R_{\\mathrm{grad}}(t) - D_{\\mathrm{grad}}(t)$ in this case yields a remarkably simple relationship with the abrupt cessation case. The dynamics of the system are linear, so we can think of the gradual case as a superposition of the abrupt case (initial conditions decaying with no input) and the response to a new constant input $k_{d}/3$. After simplification, one finds:\n$$\nC_{\\mathrm{grad}}(t) = \\frac{2}{3} \\cdot \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\exp(-k_{d} t) - \\exp(-k_{r} t) \\right].\n$$\nComparing with $C_{\\mathrm{abrupt}}(t)$, we see that:\n$$\nC_{\\mathrm{grad}}(t) = \\frac{2}{3} \\, C_{\\mathrm{abrupt}}(t) \\quad \\text{for all } t \\in [0, T].\n$$\nTherefore, the areas under the congestion curves over any horizon $[0, T]$ must be in the same ratio:\n$$\nQ_{\\mathrm{gradual}} = \\int_{0}^{T} C_{\\mathrm{grad}}(t)\\, dt = \\frac{2}{3} \\int_{0}^{T} C_{\\mathrm{abrupt}}(t)\\, dt = \\frac{2}{3} \\, Q_{\\mathrm{abrupt}}.\n$$\nHence the requested ratio is\n$$\n\\frac{Q_{\\mathrm{abrupt}}}{Q_{\\mathrm{gradual}}} = \\frac{Q_{\\mathrm{abrupt}}}{(2/3) Q_{\\mathrm{abrupt}}} = \\frac{3}{2}.\n$$\nThis result is independent of the specific values of the half-lives ($k_{d}$, $k_{r}$) and the time horizon $T$, demonstrating a fundamental property of this linear PK/PD model.",
            "answer": "$$\\boxed{\\frac{3}{2}}$$"
        }
    ]
}